Skip to main content

Venous Thromboembolism clinical trials at UC Davis
4 research studies open to eligible people

  • A Comparison Study of Oral Anticoagulants (blood thinners) for Extended VEnous Thromboembolism (blood clot in vein)

    open to eligible people ages 18 years and up

    Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.

    Orange, California

  • A Registry Study: Global Anticoagulant Registry for Venous Thromboembolic Events (blood clot in a vein)

    “We invite you to take part in a research study because you have recently been diagnosed with a blood clot in your leg or chest.”

    open to eligible people ages 18-99

    The protocol is a large registry to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic duration of anticoagulation management, clinical and economic outcomes in patients with treated acute VTE (DVT and PE) in the real-world setting. Main objectives are to clarify the: - treatment related details for acute VTE (either conventional anticoagulation therapy, treatment with a direct oral anti-coagulant or other modalities of treatment) - Rate of early and late symptomatic VTE recurrence - Rate and nature of complications of VTE including post thrombotic syndrome and chronic thromboembolic pulmonary hypertension - Rate of bleeding complications - Rate of all-cause mortality at six months

    Muscle Shoals, Alabama

  • A Study of Experimental Apixaban for Venous Thromboembolism (deep vein blood clot) in Children

    open to eligible people ages 3 months to 17 years

    To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

    Sacramento, California and other locations

  • Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

    open to eligible people ages up to 18 years

    This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.

    Sacramento, California and other locations

Last updated: